Please check your internet connection and try again.
# Rizatriptan
## Overview
Rizatriptan is a selective 5-HT1B/1D receptor agonist used for the acute treatment of migraine. It exhibits faster absorption and higher bioavailability compared to many other triptans, potentially leading to a more rapid onset of action.
## Primary Indications
Acute treatment of migraine attacks with or without aura in adults and pediatric patients.
## Adult Dosing
* **Standard Dose:** 5 mg or 10 mg orally.
* **Dose Interval:** If migraine persists or recurs, a second dose may be taken at least 2 hours after the first.
* **Maximum Dose:** 30 mg in a 24-hour period.
## Pediatric Dosing
* **Ages 6 to 17 years:**
* *Weight < 40 kg:* 5 mg.
* *Weight ≥ 40 kg:* 10 mg.
* **Dose Interval:** Single dose per 24-hour period. Safety and efficacy of a second dose in children have not been established.
## Dose Adjustments
* **Patients taking Propranolol:** Limited to 5 mg per dose, maximum of 15 mg in 24 hours. Propranolol elevates rizatriptan plasma concentrations.
* **Hepatic/Renal Impairment:** Use lower starting doses (5 mg) in patients with mild to moderate impairment. Use is not recommended in severe hepatic impairment.
## Contraindications
* History of ischemic heart disease, coronary artery vasospasm (Prinzmetal’s angina), or MI.
* History of stroke or transient ischemic attack (TIA).
* Peripheral vascular disease or ischemic bowel disease.
* Uncontrolled hypertension.
* Administration within 24 hours of another 5-HT1 agonist or ergotamine-derivative medication.
* Concurrent or recent (within 2 weeks) use of Monoamine Oxidase Inhibitors (MAOIs).
## Adverse Effects
* **Common:** Paresthesia, dizziness, somnolence, fatigue, and sensations of pressure, pain, or tightness in the chest/neck/throat (non-cardiac).
* **Serious:** Coronary vasospasm, arrhythmias, myocardial infarction, serotonin syndrome, and hypertension.
## Key Drug Interactions
* **MAOIs:** Potential for severe serotonin syndrome; contraindicated.
* **Propranolol:** Increases rizatriptan AUC by ~70%; requires dose reduction.
* **SSRIs/SNRIs:** Increased risk of serotonin syndrome; monitor for symptoms (agitation, tachycardia, hyperreflexia).
* **Ergot alkaloids:** Increased risk of coronary vasospasm; separate administration by at least 24 hours.
## Monitoring
* Assess cardiovascular status prior to first use if risk factors exist.
* Monitor for signs of serotonin syndrome, especially when combined with other serotonergic agents.
* Evaluate frequency of use; overuse (>10 days per month) may lead to medication-overuse headache.
## Clinical Pearls
* **Administration:** The orally disintegrating tablet (ODT) should be placed on the tongue and allowed to dissolve; no liquid is required. It is not faster acting than the standard tablet.
* **Efficacy:** Efficacy is highest when the medication is taken as soon as migraine symptoms begin.
* **Chest Symptoms:** Patients should be counseled that "triptan sensations" (tightness/pressure) are common but, if intense or persistent, require cardiac evaluation.
***
*Disclaimer: This information is for educational purposes only. Clinical practice guidelines and prescribing information change frequently. Always consult the latest FDA-approved labeling and official institutional protocols before making clinical decisions.*
